Alaska Heart and Vascular Institute | Anchorage, AK

Research site

(Unclaimed)

Location

3841 Piper Street Suite T-100, Anchorage, Alaska, United States of America

Site insights

Top conditions

Top treatments

Aficamten

Metoprolol Succinate

CK-3773274

Retatrutide

Omecamtiv Mecarbil

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 8 total trials

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM (FOREST-HCM)

The purpose of this study is to collect long-term safety and tolerability data for aficamten.

Invitation-only

Symptomatic Hypertrophic Cardiomyopathy (HCM)

Drug: Aficamten (5 - 20 mg)

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM (MAPLE-HCM)

The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomat...

Active, not recruiting

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Drug: Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)

Drug: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM (ACACIA-HCM)

This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients...

Enrolling

Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Drug: Aficamten

Drug: Placebo

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms